PFE, LLY, NVO, LLY and AZNS Q4

This week was loaded with profit publications by many large drug manufacturers. Novo Nordisk Nvo, Merchant MRK, Pfizer Pfe, Eli Lilly Lly, Astrazeneca Azn and Abbvie announced their results in the fourth quarter and in the year 2024. Most of these companies make estimates for both the result and sales.

Here is a summary of the most important stories of the week.

Lilly defeated estimates of the fourth quarter for profits and sales. The sale of Lillys Incretin medication, Mounjaro, Trulicity and Zepbound, missed estimates, while the medication from non-Saints exceeds expectations. Lilly’s non-Incretin revenue rose by 20%in the fourth quarter compared to the previous year. Lilly’s outlook from 2025 was also optimistic.

The turnover of $ 13.53 billion increased by 45% compared to the previous year and corresponded to the provisional number of Lilly in mid-January. Higher pharmaceutical volumes such as Mounjaro, Zepbound, Verenio, Jardiance and Tatzz were partially compensated for by lower sales of trulicity. Lilly’s new products also contributed to sales growth.

Last month, Lilly provided his sales prospects for 2025, which was maintained together with the results of the fourth quarter. In 2025, Lilly expects to achieve income in the range of $ 58.0 billion to $ 61.0 billion, which indicates growth of 32%compared to the previous year. The result per share is expected to be in the range of $ 22.50 to $ 24.00.

Novo Nordisk defeated estimates for both the result and for sales. The income rose by 30% to a constant exchange rate (CER), which was mainly driven by its GLP 1 products. The GLP-1 turnover rose by 12%at CER. The entire diabetes supply increased by 17% and the sales of obesity supply rose by 91% at CER. The sales of diabetes Drug Ozempic rose by 12%, while the injection of obesity increased by 107% at CER. Sales with rare diseases rose by 25%.

In 2025, Novo Nordisk expects sales to increase by CER by 16 to 24%, while operating profit growth will increase by 19-27%.

The results of Pfizer’s fourth quarter were strong and exceeded estimates for profits and sales. The adjusted result per share of 63 cents was much higher than 10 cents before the previous year. The income was $ 17.76 billion, which rose to an increase of 22% compared to the previous year.

Higher sales of Pfizer’s most important non-spherical products such as Vyndaqel and Eliquis and newly acquired products from SEEDEN, paired with higher Paxlovid sales, led the top in the quarter. However, the sale of some key medication such as Prevnar, Xeljanz and Ibrance and the new RSV vaccine, AberrySvo, decreased in the quarter.

The revenue from Pfizer’s non-Covid products rose by 11% in the fourth quarter and 12% in 2024. The company confirmed its financial guidelines for 2025. Pfizer expects the total turnover between USD 61.0 billion and $ 64.0 billion. The adapted result per share is expected in the range of $ 2.80 to 3.00.

Pfizer announced progression-free survival or PFS and overall survival or OS OS results from the phase III shaft breaker study for the evaluation of Barraftovi in combination with cetuximab and Molfox6 in patients with metastatic colorectal cancer with a BRAF-V600E mutation. The data showed that the Braftovi combination program was a statistically significant and clinically meaningful improvement in PFS – one of the double primary endpoints – and OS – an important secondary endpoint – in this group of patients.

The BAR combination program was approved by the FDA on a accelerated basis for treatment -naive patients with Brafv600e -Mutante -MCRC in December 2024, based on confirmed response rate data from the lens drive rate from the wave break study. The latest data is presented to the FDA to support the conversion of the accelerated approval for complete approval.

Merck defeated estimates for both the result and for sales. The adjusted profit was 1.72 USD per share compared to 3 cents in the previous year. The income rose by 7% to 15.62 billion US dollars compared to the previous year. The sale of Merck’s blockbuster cancer medication, Keytruda, rose by 21% EX FX, which was promoted by rapid recording in previous indications and the metastatic indications continued. The sale of HPV vaccines – Gardasil and Gardasil 9 – was 18%due to the lower demand in China. The sale of diabetes medication, Januvien/Janumet, decreased by 36% compared to the previous year.

Merck has published new instructions for 2025. The income is expected in the range of $ 65.6 billion in the range of $ 65.6 billion, which did not go back to the Zacks consensus estimate of $ 68.05 billion. The adapted EPS is expected in the range of $ 8.88 and $ 9.03, which also no longer leaves the Zack’s consensus estimate of $ 9.18 per share.

Abbvie announced strong results in the fourth quarter and defeated estimates for both profits and sales. While the result of $ 2.16 per share decreased by 22% compared to the previous year, sales increased by 6.1% on the basis of an operational basis, which is mainly due to a robust turnover of his immunology medication skyrizi and Rinvoq. While the sales of Skyrizi rose by 57.9%, RinvoQ’s turnover rose by 47.1%. The other key medication of Abbvie, Venclexta and Vraylar, together with significant articles from newer medication Ubrelvy, Elahere and Qulipta, have also promoted top line growth.

Abbvie has published new guidelines for 2025. The adapted EPS in the range of $ 12.12 to $ 12.32 is expected. The total revenue is expected to be around 59 billion US dollars, which, despite a negative influence of around 4% from the Medicare, corresponds to 5.7%.

The results of the fourth quarter of Astrazeneca were mixed because it missed estimates for the profit, but exceeded the same for sales. The core profit of $ 2.09 per share increased by 49%compared to the previous year, while sales rose by 25%. The income rose in all segments, whereby the sales of most key medication, including Tabrisso, Fasenra, Farxiga, Lynparka and Symbicort, defeated estimates. Astrazeneca expects the total income to increase a high single -digit percentage at CER. The core EPS is expected to increase by a low double-digit percentage.

The company said that the effects of ongoing investigations in China are still slightly on business. In December, AstraZeneca Iskra Reic appointed the new international executive Vice President, which was replaced by Leon Wang, which was arrested by the China’s authorities. The authorities in China examine some current and former Astrazeneca employees for health insurance fraud, illegal drug importation and violations of personal information.

The committee for medical products for the human use of the European medication agency gave a positive statement in which IMFINZI for the treatment of small cell lung cancer with limited level (LS-SCLC), an aggressive form of lung cancer, was recommended in the EU . The approval was based on data from the Adriatic Phase III study for LS-SCLC patients. IMFINZI approved the FDA for a similar use in LS-SCLC in November last year.

PFE, LLY, NVO and AZN each have a Zacks 3rd (hold). Here you will find the full list of today’s Zacks #1 rank (Strong Buy).

The NYSE Arca Pharmaceutical Index has increased by 1.6%in the last five trading sessions.

Large Cap Pharmaceutical Industry 5 years % return

Here is how the eight large stocks have been carried out in the last five trading sessions.

Image source: Zacks Investment Research

Abbvie increased the most (9.9%) in the last five trading sessions, while Merck declined the most (11%).

Lilly has increased the most (3.0%) in the past six months, while Nordo’s Nordisk declined the most (32%).

(See the last Pharma Stock Roundup here: Sny and Rhhby’s Q4 income & more)

Take a look at this room for regular pipeline and regulatory updates next week.

Would you like the latest recommendations from Zack’s Investment Research? Today you can download 7 best stocks for the next 30 days. Click here to receive this free report

ByAmelia Journalton

By Amelia Journalton

Related Post

Gen x women prove that 40s are not an age to slow down! Great workforce, great sex and more

Goldie Hawn’s young grandchildren see the fresh start with the fresh start after devastating experience, while the family makes big changes

Pregame Notes (game 54): Stars try to avoid Los Angeles against kings

Leave a Reply Cancel reply

You missed

Gen x women prove that 40s are not an age to slow down! Great workforce, great sex and more

Goldie Hawn’s young grandchildren see the fresh start with the fresh start after devastating experience, while the family makes big changes

Pregame Notes (game 54): Stars try to avoid Los Angeles against kings

New York Islander provide the top defender for trade